NCT06808074View on ClinicalTrials.gov

A Study to Evaluate Role of Inhaled Amikacin to Prevent Ventilator Associated Pneumonia in Patients With Cirrhosis

PHASE4RecruitingINTERVENTIONAL

Enrollment

162

Participants

Timeline

Start Date

February 12, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

May 31, 2026

Conditions

Hepatic EncephalopathyCirrhosisVentilator Associated Pneumonia (VAP)

Interventions

DRUG

Inhaled amikacin

Dosage of amikacin: 20 mg/kg based on ideal body weight, with a maximal dose of 2 g, once daily for 3 consecutive days.

DRUG

Placebo

The equivalent volume of saline solution (0.9% sodium chloride \[NaCl\]) will be administered once daily for three consecutive days

Trial Locations (2)

500032

RECRUITING

AIG Hospitals, Hyderabad

RECRUITING

Asian Institute of Gastroenterology, Hyderabad

All Listed Sponsors

lead

Asian Institute of Gastroenterology, India

OTHER

NCT06808074 - A Study to Evaluate Role of Inhaled Amikacin to Prevent Ventilator Associated Pneumonia in Patients With Cirrhosis | Biotech Hunter | Biotech Hunter